MyFinsight
Home
Blog
About
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$4,253K
Free Cash flow
-$10,655K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Cash received for sale of busine...
Accrued liabilities
Others
Negative Cash Flow Breakdown
Purchases of long-term investmen...
Purchases of short-term investme...
Net income (loss)
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-26,758
127,068
19,283
-34,687
Gain on sale of business
0
172,289
-
-
Bargain purchase gain
-
-
0
0
Indemnification-related loss
-4,212
-
-
-
Stock-based compensation expense
4,050
8,824
5,743
8,474
Amortization of acquired intangible assets
0
0
0
0
Depreciation and amortization
1,273
1,408
1,291
1,521
Accretion of discount on investments, net
1,207
632
462
611
Realized gain on equity investments
1,187
-
-
-
Unrealized loss on equity investments
952
-3,494
-602
-
Non-cash lease expense
1,245
1,355
1,584
1,570
Provision for excess and obsolete inventory
1,074
696
1,493
615
Change in fair value of warrants
0
0
0
0
Change in fair value of contingent consideration
0
0
223
0
Other non-cash items
-21
67
-17
445
Accounts receivable, net
-1,248
1,858
-6,730
5,794
Inventory
-1,249
-1,935
1,172
1,804
Prepaid expenses and other assets
1,041
1,592
-3,023
705
Deferred tax asset, non-current
5
38,359
-38,093
-
Accounts payable
1,665
-1,224
653
946
Accrued liabilities
6,645
-20,785
98
8,774
Deferred revenue
-460
-29,934
-114
700
Operating lease liabilities
-1,344
-1,490
-1,677
-1,673
Other liabilities
-7
1
-378
27
Net cash used in operating activities
-10,311
-46,597
-1,190
-22,202
Cash and restricted cash acquired in the merger
-
-
0
0
Acquisition of business, net of cash acquired
-
-
0
-
Cash received for sale of business
24,992
363,222
-
-
Purchases of short-term marketable debt securities
-
127,208
99,110
-
Purchases of short-term investments
35,967
-
-
40,312
Purchases of long-term marketable debt securities
-
58,517
32,321
-
Purchases of long-term investments
90,362
-
-
19,483
Purchases of marketable equity securities
2
837
6,857
-
Purchase of convertible note receivable
-
-
5,000
-
Proceeds from sales of equity investments
3,090
-
-
-
Proceeds from sales and maturities of investments
38,000
15,000
25,000
54,000
Purchases of property and equipment
344
570
476
886
Net cash provided by investing activities
14,408
191,090
-8,040
-6,681
Repayment of term loan and convertible notes
-
-
0
0
Payment of term loan fee
-
-
0
0
Repurchase of common stock
-
-
0
0
Proceeds from espp stock issuance
120
-
215
0
Payments for taxes related to net share settlement of equity awards and other
258
118
126
112
Proceeds from exercise of stock options
0
78
531
0
Net cash (used in) provided by financing activities
-138
-40
620
-112
Effect of foreign exchange rate fluctuations on cash and cash equivalents
294
115
-100
-203
Net increase (decrease) in cash, cash equivalents and restricted cash
4,253
144,568
-8,710
-29,198
Cash, cash equivalents and restricted cash at beginning of period
267,864
123,296
132,006
168,818
Cash, cash equivalents and restricted cash at end of period
272,117
267,864
123,296
132,006
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
something is missing
$75,001K
Proceeds from sales and
maturities of investments
$38,000K
(-62.00%↓ Y/Y)
Cash received for
sale of business
$24,992K
Proceeds from sales of
equity investments
$3,090K
Net cash provided by
investing activities
$14,408K
(-65.80%↓ Y/Y)
Effect of foreign
exchange rate...
$294K
(-74.32%↓ Y/Y)
Canceled cashflow
$126,675K
Net increase
(decrease) in cash, cash...
$4,253K
(155.86%↑ Y/Y)
Canceled cashflow
$10,449K
Purchases of long-term
investments
$90,362K
Purchases of short-term
investments
$35,967K
(-29.38%↓ Y/Y)
Purchases of property and
equipment
$344K
(-95.04%↓ Y/Y)
Purchases of marketable
equity securities
$2K
Accrued liabilities
$6,645K
(347.47%↑ Y/Y)
Indemnification-related loss
-$4,212K
Stock-based compensation
expense
$4,050K
(-73.69%↓ Y/Y)
Accounts payable
$1,665K
(98.69%↑ Y/Y)
Depreciation and
amortization
$1,273K
(-80.26%↓ Y/Y)
Inventory
-$1,249K
(-114.61%↓ Y/Y)
Accounts receivable, net
-$1,248K
(-154.33%↓ Y/Y)
Non-cash lease expense
$1,245K
(-56.54%↓ Y/Y)
Provision for excess and
obsolete inventory
$1,074K
(-21.03%↓ Y/Y)
Deferred tax asset,
non-current
$5K
Proceeds from espp stock
issuance
$120K
(-61.04%↓ Y/Y)
Net cash used in
operating activities
-$10,311K
(79.76%↑ Y/Y)
Net cash (used in)
provided by financing...
-$138K
(-322.58%↓ Y/Y)
Canceled cashflow
$22,666K
Canceled cashflow
$120K
Net income (loss)
-$26,758K
(55.02%↑ Y/Y)
Payments for taxes
related to net share...
$258K
(4.88%↑ Y/Y)
Operating lease
liabilities
-$1,344K
(56.15%↑ Y/Y)
Accretion of discount on
investments, net
$1,207K
(-23.17%↓ Y/Y)
Realized gain on equity
investments
$1,187K
Prepaid expenses and
other assets
$1,041K
(-11.40%↓ Y/Y)
Unrealized loss on equity
investments
$952K
Deferred revenue
-$460K
(75.79%↑ Y/Y)
Other non-cash items
-$21K
(-104.40%↓ Y/Y)
Other liabilities
-$7K
(-104.90%↓ Y/Y)
Buy us a coffee